美国从2025年10月1日开始对进口毒品征收100%的关税,这威胁到澳大利亚低成本药物计划和全球供应链。 U.S. 100% tariffs on imported drugs start Oct. 1, 2025, threatening Australia’s low-cost drug program and global supply chains.

美国特朗普政府计划从2025年10月1日起对进口品牌药品征收100%的关税 — — 除非制造商建造美国设施 — — 威胁着澳大利亚180亿美元的药品福利计划,该计划保持药品价格低廉。 The U.S. Trump administration’s plan to impose a 100% tariff on imported branded pharmaceuticals starting October 1, 2025—unless manufacturers build U.S. facilities—threatens Australia’s $18 billion Pharmaceutical Benefits Scheme, which keeps drug prices low. 该政策有可能干扰基本药品的获取,特别是对弱势人口而言,并导致库存急剧下降,尽管CSL和Pro Medicus等公司表示它们不受影响。 The policy risks disrupting access to essential medicines, especially for vulnerable populations, and has caused sharp stock drops, though some companies like CSL and Pro Medicus say they are unaffected. 全球市场的反应是波动,随后是反弹,反映了人们对美国贸易政策的转变及其对全球供应链和公共卫生系统的影响的广泛关切。 Global markets reacted with volatility, followed by rebounds, reflecting widespread concern over U.S. trade policy shifts and their impact on global supply chains and public health systems.